Provider Briefing: The Ceftriaxone Shortage in 2026

Ceftriaxone Sodium Injection — the third-generation cephalosporin that serves as a backbone of empiric therapy in emergency departments, inpatient units, and outpatient infusion centers — remains in active shortage as of early 2026. This briefing covers what providers need to know to navigate the shortage, protect patient outcomes, and access available supply.

For a patient-facing overview of the shortage, see our Ceftriaxone shortage update for patients.

Shortage Timeline

The current Ceftriaxone shortage has been building over several years:

• 2010-2017: Recurring episodic shortages driven by manufacturing disruptions at individual facilities
• 2020: COVID-19 pandemic strains global pharmaceutical supply chains, increasing demand for injectable antibiotics in hospital settings
• 2023: Shortage escalates significantly. Hikma Pharmaceuticals reports manufacturing delays. Lupin Pharmaceuticals begins winding down Ceftriaxone production.
• 2024: ASHP formally lists Ceftriaxone Sodium Injection on the Drug Shortages database. Multiple formulations affected, with particular pressure on 1 g and 2 g vials and premixed IV bags.
• 2025: Lupin completes discontinuation of all Ceftriaxone presentations. Remaining manufacturers (Hikma, Sandoz, Apotex, Fresenius Kabi, WG Critical Care) continue production with intermittent allocation limits.
• 2026: Shortage continues. Supply remains inconsistent with regional variability. No new manufacturers have entered the market.

Prescribing Implications

The shortage creates several clinical challenges that prescribers should address proactively:

Empiric Therapy Selection

When Ceftriaxone is unavailable for empiric therapy, consider the following evidence-based alternatives by indication:

• Community-acquired pneumonia: Cefotaxime 1-2 g IV q8h; or consider Ampicillin-Sulbactam 3 g IV q6h for non-ICU patients; Levofloxacin 750 mg IV daily as monotherapy alternative
• Bacterial meningitis: Cefotaxime 2 g IV q4-6h is the primary alternative (similar CSF penetration and bactericidal activity)
• Uncomplicated gonorrhea: Per 2021 CDC STI guidelines, Ceftriaxone 500 mg IM is preferred. If unavailable, Gentamicin 240 mg IM plus Azithromycin 2 g orally is an alternative regimen
• UTI/pyelonephritis: Cefepime 2 g IV q12h; or Ertapenem 1 g IV daily for complicated cases; oral step-down with Cefpodoxime or fluoroquinolones when appropriate
• Lyme disease (neuroborreliosis): Cefotaxime 2 g IV q8h; or oral Doxycycline 200 mg daily for 14-28 days in patients who can take oral therapy
• Surgical prophylaxis: Cefazolin remains preferred when available; Cefotaxime or Cefuroxime as alternatives

Antimicrobial Stewardship Considerations

During shortages, the temptation to use broader-spectrum agents like carbapenems increases. Stewardship teams should:

• Develop institution-specific substitution protocols based on current Ceftriaxone allocation levels
• Monitor carbapenem utilization to prevent unnecessary escalation
• Encourage early IV-to-oral conversion when clinically appropriate to conserve injectable supply
• Review automated order sets and clinical pathways that default to Ceftriaxone

Dosing and Formulation Flexibility

Encourage flexibility across available formulations:

• If 1 g vials are unavailable, two 500 mg vials can be used to prepare a 1 g dose
• If powder vials are unavailable, premixed frozen bags may be available (and vice versa)
• Pharmacy departments should maintain cross-referenced allocation lists and communicate availability changes in real time

Current Availability Picture

Availability varies significantly by region, distributor, and healthcare system. Key data points:

• Active manufacturers: Hikma (with delays), Sandoz, Apotex, Fresenius Kabi, WG Critical Care
• Discontinued: Lupin (all presentations), Roche (Rocephin brand, discontinued prior to current shortage)
• Most affected formulations: 1 g and 2 g powder vials, premixed frozen IV bags
• Wholesaler allocation: Many wholesalers have implemented allocation limits, restricting the volume individual facilities can order

For real-time availability checking, providers can direct patients to Medfinder for Providers, which tracks pharmacy stock levels across regions.

Cost and Access Considerations

Ceftriaxone remains an affordable generic when available:

• Hospital acquisition cost: Approximately $2 to $15 per 1 g vial depending on contract pricing and GPO agreements
• Patient cash price (outpatient): $20 to $55 per 1 g vial without insurance; as low as $4.61 to $6.60 with discount coupons
• Administration costs: Facility fees for IV infusion range from $100 to $500+ depending on payer and setting

For patients facing financial barriers, providers can suggest discount programs (GoodRx, SingleCare) and patient assistance resources (NeedyMeds, RxAssist). For a comprehensive guide you can share with patients, see how to save money on Ceftriaxone.

Tools and Resources for Providers

• Medfinder for Providers — Real-time medication availability tracking across pharmacies and clinics. Help patients locate Ceftriaxone in stock near them.
• ASHP Drug Shortages Database (ashp.org/drug-shortages) — Official shortage listings with manufacturer-specific status updates
• FDA Drug Shortage Database (accessdata.fda.gov/scripts/drugshortages) — Federal shortage tracking and manufacturer communications
• CDC STI Treatment Guidelines — Updated alternative regimens when preferred agents are unavailable
• IDSA Practice Guidelines — Infection-specific recommendations for alternative antibiotic selection

Looking Ahead

The structural factors driving the Ceftriaxone shortage — manufacturer consolidation, low margins on generic sterile injectables, and aging manufacturing infrastructure — are unlikely to resolve quickly. Providers should:

• Build shortage-aware protocols into standard workflows now rather than treating this as temporary
• Maintain familiarity with alternative regimens across common indications
• Communicate proactively with patients about why their preferred antibiotic may not be available, and provide a clear plan
• Leverage tools like Medfinder for Providers to reduce the administrative burden of tracking down medication supply

For a practical guide on workflow integration, see our companion post: How to help your patients find Ceftriaxone in stock.

Final Thoughts

The Ceftriaxone shortage is a symptom of deeper problems in the generic sterile injectable market. Until manufacturing capacity expands and the economics improve for generic producers, shortages of critical antibiotics like Ceftriaxone will remain a reality for providers and patients alike.

In the meantime, evidence-based alternative regimens exist for nearly every indication. Staying informed, building flexible protocols, and using real-time tools like Medfinder can help ensure patients receive effective treatment even when first-line options are constrained.